Cancer Research Consortium of West Michigan
P: 616.391.1230 | 800.336.6299 | www.crcwm.org

Fast Facts

Molecular Analysis for Therapy Choice (MATCH)

MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification

Schema



Cycle = 21 days
Accrual Goal: 35

ELIGIBILITY CRITERIA

1. **Patients must fulfill all eligibility criteria outlined in Section 3.1 of MATCH Master Protocol (excluding Sections 3.1.6, 3.1.7 and 3.1.11) at the time of registration to treatment step (Step 1, 3, 5, 7).**
2. **Patients must have HER2 amplification ≥ 7 copy numbers by NGS as determined by the MATCH screening assessment. See Appendix I for a list of the HER2 amplification and corresponding Levels of Evidence.**
3. **Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block).**
   Date of ECG: _____
4. **Patients must have ECHO or MUGA within 4 weeks prior to treatment assignment and must not have a left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN). If the LLN is not defined at a site, the LVEF must be ≥ 50% for the patient to be eligible.**
   Date of ECHO/MUGA: _____
5. **Patients must not have breast cancer, gastric/GEJ/esophageal adenocarcinoma or mixed histology, or gastric/GEJ NOS tumors.**

6. **Patients must not have known hypersensitivity to trastuzumab or pertuzumab or compounds of similar chemical or biologic composition.**
7. **Patients must not have received prior anti-HER2 therapies, including trastuzumab, pertuzumab, T-DM1, lapatinib, afatinib, neratinib, dacomitinib, canertinib.**
8. **Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must agree to use adequate contraception (hormonal or double barrier method of birth control; abstinence from one week prior to study treatment starting, during treatment, and for a period of 7 months after the last dose of study treatment.**

Study Parameters

Test/Assessment	Prior to Registration to Treatment	Treatment		End of Treatment	Follow Up[L]
		Every Cycle, prior to treatment	Every 3 Cycles		
H&P, Weight, Vital signs[A]	X	X[K]			X
Performance status	X	X[K]			X
Concomitant Medication Review[B]					
CBC w/diff, plts[C]	X	X[K]			X
Serum chemistry[C]	X	X[K]			X
Radiologic evaluation[D]	X		X[D]		X[L]
β-HCG[E]	X				
Toxicity Assessment[F]		X		X	X[L]
ECG[G]	X[J]				
ECHO/Nuclear Study[H]	X[H]			X[H]	
Tumor biopsy and blood sample for MATCH Master Protocol[I]			X	X	